Costs keep older rural cancer survivors away from health services

Share this article:

Reducing disparities between urban and rural health care may involve addressing out-of-pocket costs, particularly for older persons who have survived cancer, researchers found.

Financial difficulties may interfere with a cancer survivor's ability to seek the routine follow-up care recommended to promote his or her well-being. Although urban-rural disparities have been seen in the general population in terms of abstaining from health care services due to cost, it was unknown whether this disparity persists among cancer survivors.

Nynikka R.A. Palmer, DrPH, MPH, of the Wake Forest School of Medicine in Winston-Salem, North Carolina, and colleagues analyzed data from 7,804 cancer survivors participating in the National Health Interview Survey from 2006 to 2010.  They stratified the participants by younger age (18 to 64 years; n=3,799) and older age (65 years and older; n=4,005).

Overall, the investigators found that rural cancer survivors were more likely than their urban counterparts to delay or do without medical care because of cost, particularly older survivors. Survivors with public or no insurance, and those with more comorbidities and in poor health, were more likely than others to forgo care.

Rural-urban disparities in the forgoing of medical and dental care persisted for older survivors but not for younger survivors after adjustments for clinical and sociodemographic characteristics. The fact that no disparity was noted in terms of forgoing prescription medications was likely due to enhanced prescription drug coverage through Medicare, wrote Palmer and coauthors in Cancer Epidemiology, Biomarkers & Prevention (2013;22:1668-1676).

Yet despite Medicare, older rural survivors are still forgoing care because of cost at higher rates than urban survivors, noted the researchers, who theorized that out-of-pocket costs may be a significant reason for this.

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

JAK inhibitors promising in colorectal cancer

JAK inhibitors have been found to halt tumor growth in colorectal cancer with a certain genetic mutation, according to a new study.

Pertuzumab adds survival benefit for HER2-positive breast cancer

Patients with HER2-positive breast cancer that has metastasized demonstrate longer survival outcomes if treated with a combination of pertuzumab, trastuzumab, and chemotherapy.

IMPRESS trial fails to find benefit from more tyrosine kinase inhibitor (TKI) ...

Patients with lung cancer that have developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival when continued use of the drug with chemotherapy is utilized.